Physician profile
Barry S Brown
NPI 1184628737
$12,387.79
in general payments reported to CMS, 2019-2025
48 companies · $1,887 in 2025
The $1,887 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $1,269 · 2021: $2,252 · 2022: $2,007 · 2023: $2,184 · 2024: $2,320 · 2025: $1,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,301 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,301.39 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,191.77 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,612.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $844.17 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Abbott Laboratories | $700.95 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $692.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $670.82 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $631.47 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $486.51 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $432.54 | 2022-2025 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $397.62 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| E.R. Squibb & Sons, L.L.C. | $359.59 | 2019-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.28 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $303.95 | 2021-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $298.62 | 2023-2025 | |
| Amgen INC. | $289.36 | 2022-2025 | Repatha, Otezla, Repatha |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.